Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
About the study
The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Male and female patients ≥18 years of age with Sporadic or familial ALS
- If taking riluzole and/or edaravone, must be on a stable dose prior to Screening.
EXCLUSION CRITERIA
Exclusion Criteria:
- History of a clinically significant non-ALS neurologic disorder
- Inability to swallow capsules.
- Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus
- Women who are pregnant, planning to become pregnant, or are breastfeeding.
- Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
- Current or anticipated need of a diaphragm pacing system (DPS).
- Currently using glucocorticoids or have a history of regular systemic glucocorticoid use within the last 12 months.
- Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Amyotrophic Lateral Sclerosis
Age (in years)
18+
Phase
Phase 2
Participants needed
198
Est. Completion Date
Nov 30, 2024
Treatment type
Interventional
Sponsor
Corcept Therapeutics
ClinicalTrials.gov identifier
NCT05407324
Study number
CORT113176-652
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?